

AMENDMENTS TO THE SPECIFICATION

Kindly delete the paragraph beginning at line 15 on page 5 of the specification and ending at line 33 on page 5 of the specification and replace it with the following:

-- Advantageously, in the formulations of the invention, precipitation of CCI-779 upon dilution with aqueous infusion solutions or blood is prevented through the use of a surfactant contained in the diluent solution. The most important component of the diluent is a parenterally acceptable surfactant. One particularly desirable surfactant is polysorbate 20 or polysorbate 80. However, one of skill in the art may readily select other suitable surfactants from among salts of bile acids (taurocholate, glycocholate, cholate, deoxycholate, etc.) which are optionally combined with lecithin. Alternatively, ethoxylated vegetable oils, such as a pegylated castor oil [e.g., such as PEG-35 castor oil which is sold, e.g., under the name ~~Cremophor EL~~ CREMOPHOR® EL polyethyleneglycerol triricinoleat 35 (polyethoxy 35 castor oil), BASF], vitamin E tocopherol propylene glycol succinate (Vitamin E TGPS), and polyoxyethylene-polyoxypropylene block copolymers can be used in the diluent as a surfactant, as well as other members of the polysorbate family such as polysorbate 20 or 60. Other components of the diluent may include water, ethanol, polyethylene glycol 300, polyethylene 400, polyethylene 600, polyethylene 1000, or blends containing one or more of these polyethylene glycols, propylene glycol and other parenterally acceptable cosolvents or agents to adjust solution osmolarity such as sodium chloride, lactose, mannitol or other parenterally acceptable sugars, polyols and electrolytes. It is expected that the surfactant will comprise 2 to 100% w/v of the diluent solution, 5 to 80% w/v, 10 to 75% w/v, 15 to 60 % w/v, and preferably, at least 5% w/v, or at least 10% w/v, of the diluent solution. --

Kindly delete the paragraph beginning at line 17 on page 8 of the specification and ending at line 19 on page 8 of the specification and replace it with the following:

-- **Example 5**

~~Cremopher~~CREMOPHOR® EL polyethoxy 35 castor oil 10 w/v%
Water for Injection q.s. 100 w/v%

--

Kindly delete the "ABSTRACT OF THE DISCLOSURE" and replace it with the following. A separate page with the new Abstract is being supplied.

-- **ABSTRACT OF THE DISCLOSURE**

~~This invention provides parenteral~~Parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779)are provided. One parenteral formulation contains CCI-779, an alcoholic co-solvent, and an antioxidant. Another parenteral formulation contains CCI-779, an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant. Processes for preparing parenteral CCI-779 formulations using a co-solvent concentrate are also provided.

--